Australia's most trusted source of pharma news
Wednesday, 03 March 2021
News Headlines
SEARCH NOW
News
Senior US exec joins Aus firm
Posted 23 February 2021 AM
An Australian company that is using real world evidence to back regulatory filings for a new cannabinoid medicine designed to reduce symptoms of anxiety, depression and stress has appointed a senior US pharma executive to lead its Strategic Advisory Board.
Dr Karen Smith, who has served as chief medical officer for Jazz Pharmaceuticals among other roles will chair the board for ASX-listed Emyria.
Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here
Posted 23 February 2021 AM
An Australian company that is using real world evidence to back regulatory filings for a new cannabinoid medicine designed to reduce symptoms of anxiety, depression and stress has appointed a senior US pharma executive to lead its Strategic Advisory Board.
Dr Karen Smith, who has served as chief medical officer for Jazz Pharmaceuticals among other roles will chair the board for ASX-listed Emyria.
Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here
Approvals Action
Pfizer vs Humira
Adds to a growing list of adalimumab biosims
Adds to a growing list of adalimumab biosims
Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
In the face of deep change, is piecemeal enough?
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas
UPDATE: Distribution of two mRNA vaccines overseas